Résultats de la recherche

search
immunocore-logo-2018
Immunocore reports fourth quarter and full year 2024 financial results and provides a business update
26 févr. 2025 07h00 HE | Immunocore Holdings plc
KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 Executing on KIMMTRAK lifecycle management with two Phase 3 trials...
immunocore-logo-2018
Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025
19 févr. 2025 07h00 HE | Immunocore Holdings plc
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 19 February 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology...
immunocore-logo-2018
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
10 janv. 2025 07h00 HE | Immunocore Holdings plc
 Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3 trials across multiple melanoma...
immunocore-logo-2018
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 07h00 HE | Immunocore Holdings plc
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 6 January 2025) Immunocore Holdings plc...
immunocore-logo-2018
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
02 janv. 2025 07h00 HE | Immunocore Holdings plc
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. &...
immunocore-logo-2018
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
23 déc. 2024 07h00 HE | Immunocore Holdings plc
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME IMC-P115C (PRAME-HLE-A02) targets...
immunocore-logo-2018
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
17 déc. 2024 07h00 HE | Immunocore Holdings plc
The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with advanced cancers expressing PIWIL1 First...
immunocore-logo-2018
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
11 déc. 2024 07h00 HE | Immunocore Holdings plc
ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant treatment with tebentafusp can decrease the risk of relapse, compared to...
immunocore-logo-2018
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
03 déc. 2024 01h00 HE | Immunocore Holdings plc
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma (OXFORDSHIRE, England &...
immunocore-logo-2018
Immunocore to present at upcoming investor conferences
08 nov. 2024 07h00 HE | Immunocore Holdings plc
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 8 November 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology...